Last reviewed · How we verify
mFolfox6 or capecitabine
capecitabine is a prodrug that is converted into 5-fluorouracil, which is then incorporated into DNA and RNA, interfering with cancer cell replication.
capecitabine is a prodrug that is converted into 5-fluorouracil, which is then incorporated into DNA and RNA, interfering with cancer cell replication. Used for Adjuvant treatment of stage III colon cancer, Advanced colorectal cancer, Metastatic breast cancer.
At a glance
| Generic name | mFolfox6 or capecitabine |
|---|---|
| Sponsor | UNICANCER |
| Drug class | pyrimidine analog |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This process is known as nucleotide analog inhibition. As a result, cancer cells are unable to divide and grow, leading to cell death. This mechanism is specific to rapidly dividing cells, such as cancer cells.
Approved indications
- Adjuvant treatment of stage III colon cancer
- Advanced colorectal cancer
- Metastatic breast cancer
- Metastatic colorectal cancer
- Metastatic gastric cancer
- Metastatic pancreatic cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (PHASE1, PHASE2)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (PHASE1, PHASE2)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (PHASE2, PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (PHASE2)
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (PHASE1)
- Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |